Manuel Serrano and Senolytics
Serrano researches cellular senescence at IRB Barcelona; the Senolytics glossary card describes a six-month nonhuman-primate trial of dasatinib plus quercetin that reduced senescence-marker gene expression and circulating PAI-1 and MMP-9.
Manuel Serrano leads a group at IRB Barcelona, studying cellular senescence, tissue plasticity, and in vivo reprogramming as mechanisms of aging and disease and as potential therapeutic approaches. Senolytics are a class of interventions with one purpose: to selectively eliminate senescent cells.
The connection is direct: Serrano researches cellular senescence; senolytics target senescent cells for elimination. His specific contribution to any senolytic compound is not established by the available data.
The Senolytics glossary card describes a six-month trial in middle-aged nonhuman primates: monthly dasatinib plus quercetin reduced adipose senescence-marker gene expression and circulating PAI-1 and MMP-9. The investigators reported anti-inflammatory immune shifts, reduced microbial-translocation biomarkers, and improved blood urea nitrogen. They assessed the regimen as safe over the exposure period and called for larger controlled trials in older patients.
The edge connects a cellular senescence researcher to the intervention class that targets senescent cells directly, making the biological link easy to follow and informative for readers new to either endpoint.